Cargando…
Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts
INTRODUCTION: Systemic sclerosis (SSc) is a complex and not fully understood autoimmune disease associated with fibrosis of multiple organs. The main effector cells, the myofibroblasts, are collagen-producing cells derived from the activation of resting fibroblasts. This process is regulated by a co...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4566861/ https://www.ncbi.nlm.nih.gov/pubmed/26357964 http://dx.doi.org/10.1186/s13075-015-0754-7 |
_version_ | 1782389736973795328 |
---|---|
author | Cipriani, Paola Di Benedetto, Paola Ruscitti, Piero Verzella, Daniela Fischietti, Mariafausta Zazzeroni, Francesca Liakouli, Vasiliki Carubbi, Francesco Berardicurti, Onorina Alesse, Edoardo Giacomelli, Roberto |
author_facet | Cipriani, Paola Di Benedetto, Paola Ruscitti, Piero Verzella, Daniela Fischietti, Mariafausta Zazzeroni, Francesca Liakouli, Vasiliki Carubbi, Francesco Berardicurti, Onorina Alesse, Edoardo Giacomelli, Roberto |
author_sort | Cipriani, Paola |
collection | PubMed |
description | INTRODUCTION: Systemic sclerosis (SSc) is a complex and not fully understood autoimmune disease associated with fibrosis of multiple organs. The main effector cells, the myofibroblasts, are collagen-producing cells derived from the activation of resting fibroblasts. This process is regulated by a complex repertoire of profibrotic cytokines, and among them transforming growth factor beta (TGF-β) and endothelin-1 (ET-1) play a major role. In this paper we show that TGF-β and ET-1 receptors co-operate in myofibroblast activation, and macitentan, an ET-1 receptor antagonist binding ET-1 receptors, might interfere with both TGF-β and ET-1 pathways, preventing myofibroblast differentiation. METHODS: Fibroblasts isolated from healthy controls and SSc patients were treated with TGF-β and ET-1 and successively analyzed for alpha smooth muscle actin (α-SMA) and collagen (Col1A1) expression and for the Sma and Mad Related (SMAD) phosphorylation. We further tested the ability of macitentan to interfere with these process. Furthermore, we silenced ET-1 and endothelin-1 receptor A expression and evaluated the formation of an ET-1/TGF-β receptor complex by immunoprecitation assay. RESULTS: We showed myofibroblast activation in SSc fibroblasts assessing the expression of α-SMA and Col1A1, after stimulation with TGF-β and ET-1. Macitentan interfered with both ET-1- and TGF-β-induced fibroblast activation. To explain this unexpected inhibitory effect of macitentan on TGF-β activity, we silenced ET-1 expression on SSc fibroblasts and co-immunoprecipitated these two receptors, showing the formation of an ET-1/TGF-β receptor complex. CONCLUSIONS: During SSc, ET-1 produced by activated endothelia contributes to myofibroblast activation using TGF-β machinery via an ET-1/TGF-β receptor complex. Macitentan interferes with the profibrotic action of TGF-β, blocking the ET-1 receptor portion of the ET-1/TGF-β receptor complex. |
format | Online Article Text |
id | pubmed-4566861 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-45668612015-09-12 Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts Cipriani, Paola Di Benedetto, Paola Ruscitti, Piero Verzella, Daniela Fischietti, Mariafausta Zazzeroni, Francesca Liakouli, Vasiliki Carubbi, Francesco Berardicurti, Onorina Alesse, Edoardo Giacomelli, Roberto Arthritis Res Ther Research Article INTRODUCTION: Systemic sclerosis (SSc) is a complex and not fully understood autoimmune disease associated with fibrosis of multiple organs. The main effector cells, the myofibroblasts, are collagen-producing cells derived from the activation of resting fibroblasts. This process is regulated by a complex repertoire of profibrotic cytokines, and among them transforming growth factor beta (TGF-β) and endothelin-1 (ET-1) play a major role. In this paper we show that TGF-β and ET-1 receptors co-operate in myofibroblast activation, and macitentan, an ET-1 receptor antagonist binding ET-1 receptors, might interfere with both TGF-β and ET-1 pathways, preventing myofibroblast differentiation. METHODS: Fibroblasts isolated from healthy controls and SSc patients were treated with TGF-β and ET-1 and successively analyzed for alpha smooth muscle actin (α-SMA) and collagen (Col1A1) expression and for the Sma and Mad Related (SMAD) phosphorylation. We further tested the ability of macitentan to interfere with these process. Furthermore, we silenced ET-1 and endothelin-1 receptor A expression and evaluated the formation of an ET-1/TGF-β receptor complex by immunoprecitation assay. RESULTS: We showed myofibroblast activation in SSc fibroblasts assessing the expression of α-SMA and Col1A1, after stimulation with TGF-β and ET-1. Macitentan interfered with both ET-1- and TGF-β-induced fibroblast activation. To explain this unexpected inhibitory effect of macitentan on TGF-β activity, we silenced ET-1 expression on SSc fibroblasts and co-immunoprecipitated these two receptors, showing the formation of an ET-1/TGF-β receptor complex. CONCLUSIONS: During SSc, ET-1 produced by activated endothelia contributes to myofibroblast activation using TGF-β machinery via an ET-1/TGF-β receptor complex. Macitentan interferes with the profibrotic action of TGF-β, blocking the ET-1 receptor portion of the ET-1/TGF-β receptor complex. BioMed Central 2015-09-10 2015 /pmc/articles/PMC4566861/ /pubmed/26357964 http://dx.doi.org/10.1186/s13075-015-0754-7 Text en © Cipriani et al. 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Cipriani, Paola Di Benedetto, Paola Ruscitti, Piero Verzella, Daniela Fischietti, Mariafausta Zazzeroni, Francesca Liakouli, Vasiliki Carubbi, Francesco Berardicurti, Onorina Alesse, Edoardo Giacomelli, Roberto Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts |
title | Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts |
title_full | Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts |
title_fullStr | Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts |
title_full_unstemmed | Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts |
title_short | Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts |
title_sort | macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the etr/tβri complex in systemic sclerosis dermal fibroblasts |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4566861/ https://www.ncbi.nlm.nih.gov/pubmed/26357964 http://dx.doi.org/10.1186/s13075-015-0754-7 |
work_keys_str_mv | AT ciprianipaola macitentaninhibitsthetransforminggrowthfactorbprofibroticactionblockingthesignalingmediatedbytheetrtbricomplexinsystemicsclerosisdermalfibroblasts AT dibenedettopaola macitentaninhibitsthetransforminggrowthfactorbprofibroticactionblockingthesignalingmediatedbytheetrtbricomplexinsystemicsclerosisdermalfibroblasts AT ruscittipiero macitentaninhibitsthetransforminggrowthfactorbprofibroticactionblockingthesignalingmediatedbytheetrtbricomplexinsystemicsclerosisdermalfibroblasts AT verzelladaniela macitentaninhibitsthetransforminggrowthfactorbprofibroticactionblockingthesignalingmediatedbytheetrtbricomplexinsystemicsclerosisdermalfibroblasts AT fischiettimariafausta macitentaninhibitsthetransforminggrowthfactorbprofibroticactionblockingthesignalingmediatedbytheetrtbricomplexinsystemicsclerosisdermalfibroblasts AT zazzeronifrancesca macitentaninhibitsthetransforminggrowthfactorbprofibroticactionblockingthesignalingmediatedbytheetrtbricomplexinsystemicsclerosisdermalfibroblasts AT liakoulivasiliki macitentaninhibitsthetransforminggrowthfactorbprofibroticactionblockingthesignalingmediatedbytheetrtbricomplexinsystemicsclerosisdermalfibroblasts AT carubbifrancesco macitentaninhibitsthetransforminggrowthfactorbprofibroticactionblockingthesignalingmediatedbytheetrtbricomplexinsystemicsclerosisdermalfibroblasts AT berardicurtionorina macitentaninhibitsthetransforminggrowthfactorbprofibroticactionblockingthesignalingmediatedbytheetrtbricomplexinsystemicsclerosisdermalfibroblasts AT alesseedoardo macitentaninhibitsthetransforminggrowthfactorbprofibroticactionblockingthesignalingmediatedbytheetrtbricomplexinsystemicsclerosisdermalfibroblasts AT giacomelliroberto macitentaninhibitsthetransforminggrowthfactorbprofibroticactionblockingthesignalingmediatedbytheetrtbricomplexinsystemicsclerosisdermalfibroblasts |